Compounds > tak 779
Page last updated: 2024-09-05

tak 779 and Prostatic Neoplasms

tak 779 has been researched along with Prostatic Neoplasms in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arnatt, CK; Gewirtz, DA; Haney, KM; Li, G; Ware, JL; Yuan, Y; Zhang, F; Zhang, Y1
Arnatt, CK; Bajacan, JE; Fang, HC; Haney, KM; Richardson, AC; Ware, JL; Zhang, F; Zhang, Y1
Adams, JL; Arnatt, CK; Haney, KM; Li, G; Zhang, Y; Zhang, Z1
Kadam, PA; Lawrence, DM; Peehl, DM; Vaday, GG1

Other Studies

4 other study(ies) available for tak 779 and Prostatic Neoplasms

ArticleYear
The natural product CCR5 antagonist anibamine and its analogs as anti-prostate cancer agents.
    Bioorganic & medicinal chemistry letters, 2011, Sep-15, Volume: 21, Issue:18

    Topics: Antineoplastic Agents; Biological Products; CCR5 Receptor Antagonists; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Male; Molecular Structure; Prostatic Neoplasms; Pyridines; Receptors, CCR5; Stereoisomerism; Structure-Activity Relationship

2011
Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.
    European journal of medicinal chemistry, 2012, Volume: 55

    Topics: Animals; Antineoplastic Agents; Biological Products; Calcium; CCR5 Receptor Antagonists; Cell Line, Tumor; Cell Proliferation; Chemokine CCL5; Drug Discovery; Humans; Male; Mice; NIH 3T3 Cells; Prostatic Neoplasms; Pyridines; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2012
Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents.
    Bioorganic & medicinal chemistry letters, 2014, May-15, Volume: 24, Issue:10

    Topics: Antineoplastic Agents; CCR5 Receptor Antagonists; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Male; Piperazines; Prostatic Neoplasms; Structure-Activity Relationship

2014
Expression of CCL5 (RANTES) and CCR5 in prostate cancer.
    The Prostate, 2006, Feb-01, Volume: 66, Issue:2

    Topics: Adenocarcinoma; Amides; Autocrine Communication; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Chemokine CCL5; Chemokines, CC; Disease Progression; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Quaternary Ammonium Compounds; Receptors, CCR5; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger

2006